Sintilimab plus IBI305 for hepatocellular carcinoma

Lancet Oncol. 2021 Sep;22(9):e386. doi: 10.1016/S1470-2045(21)00388-0.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Carcinoma, Hepatocellular* / drug therapy
  • Carcinoma, Hepatocellular* / epidemiology
  • Humans
  • Liver Neoplasms* / drug therapy

Substances

  • Antibodies, Monoclonal, Humanized
  • sintilimab